PharmAlert.net

PharmAlert Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Chantix, a drug to help adults quit smoking: FDA has updated label to include potential alcohol interaction


The FDA ( Food and Drug Administration ) is warning that the prescription smoking cessation medicine Chantix ( Varenicline ) can change the way people react to alcohol.
Interactions between alcohol and Chantix have resulted in some patients experiencing increased intoxicating effects of alcohol, sometimes associated with aggressive behavior and/or amnesia.
In addition, rare accounts of seizures in patients treated with Chantix have been reported.

FDA has approved changes to the Chantix label to warn about these risks.

Chantix is a prescription medicine that is FDA-approved to help adults quit smoking.

Recommendation

Healthcare professionals should weigh the potential risk of seizures against the potential benefits before prescribing Chantix in patients with a history of seizures or other factors that can lower the seizure threshold.

Advise patients to immediately stop taking Chantix if they develop agitation, hostility, aggressive behavior, depressed mood, or changes in behavior or thinking that are not typical for them, or if they develop suicidal ideation or behavior.

Until patients know how Chantix affects their ability to tolerate alcohol, they should decrease the amount of alcohol they drink. Patients who have a seizure while taking Chantix should stop the medicine and seek medical attention immediately. ( Xagena )

Source: FDA, 2015

XagenaMedicine_2015



Indietro